| 15/09/26 | 07:00:06 | 15 Sept 2026 | | GSK to acquire T cell-engager for multiple myeloma | RNS |
| 14/09/26 | 07:00:11 | 14 Sept 2026 | | Ris-Rez Positive Ph 3 OS Lung Cancer Data in China | RNS |
| 14/09/26 | 07:00:11 | 14 Sept 2026 | | Jideytro positive data for ROS1-positive NSCLC | RNS |
| 11/09/26 | 15:30:00 | 11 Sept 2026 | | Director/PDMR Shareholding | RNS |
| 10/09/26 | 15:30:00 | 10 Sept 2026 | | Director/PDMR Shareholding | RNS |
| 10/09/26 | 07:00:05 | 10 Sept 2026 | | Japan approval of Shingrix in a prefilled syringe | RNS |
| 09/09/26 | 15:30:01 | 9 Sept 2026 | | Director/PDMR Shareholding | RNS |
| 09/09/26 | 15:30:01 | 9 Sept 2026 | | Director/PDMR Shareholding | RNS |
| 01/09/26 | 15:00:00 | 1 Sept 2026 | | Total Voting Rights | RNS |
| 01/09/26 | 07:00:14 | 1 Sept 2026 | | mRNA flu vaccine candidate to advance to phase III | RNS |
| 26/08/26 | 15:30:00 | 26 Aug 2026 | | Director/PDMR Shareholding | RNS |
| 24/08/26 | 15:30:00 | 24 Aug 2026 | | Director/PDMR Shareholding | RNS |
| 24/08/26 | 07:02:01 | 24 Aug 2026 | | First global approval for Hibsago in Japan | RNS |
| 24/08/26 | 07:00:09 | 24 Aug 2026 | | US FDA to review Jemperli for rectal cancer | RNS |
| 13/08/26 | 15:33:39 | 13 Aug 2026 | | Director/PDMR Shareholding | RNS |
| 11/08/26 | 15:30:00 | 11 Aug 2026 | | Director/PDMR Shareholding | RNS |
| 03/08/26 | 15:00:00 | 3 Aug 2026 | | Total Voting Rights | RNS |
| 30/07/26 | 15:30:00 | 30 Jul 2026 | | Director/PDMR Shareholding | RNS |
| 28/07/26 | 12:05:01 | 28 Jul 2026 | | New GSK flagship R&D centre in Cambridge | RNS |
| 28/07/26 | 12:00:00 | 28 Jul 2026 | | 2nd Quarter Results | RNS |
| 28/07/26 | 11:06:50 | 28 Jul 2026 | | Hansoh positive 2nd Phase III results for Riz-Rez | RNS |
| 24/07/26 | 15:30:00 | 24 Jul 2026 | | Director/PDMR Shareholding | RNS |
| 24/07/26 | 15:00:00 | 24 Jul 2026 | | Admission to Trading | RNS |
| 22/07/26 | 17:22:55 | 22 Jul 2026 | | Jideytro approved in US for certain lung cancers | RNS |
| 20/07/26 | 07:00:07 | 20 Jul 2026 | | Bexsero 1-dose booster EMA file acceptance | RNS |
| 17/07/26 | 12:00:01 | 17 Jul 2026 | | Audit tender conclusion | RNS |
| 17/07/26 | 09:30:00 | 17 Jul 2026 | | Camlipixant phase III results update | RNS |
| 16/07/26 | 15:30:00 | 16 Jul 2026 | | Director/PDMR Shareholding | RNS |
| 15/07/26 | 13:38:08 | 15 Jul 2026 | | GSK completes acquisition of Nuvalent, Inc | RNS |
| 14/07/26 | 15:30:01 | 14 Jul 2026 | | Director/PDMR Shareholding | RNS |
| 13/07/26 | 15:30:00 | 13 Jul 2026 | | Director/PDMR Shareholding | RNS |
| 13/07/26 | 07:00:10 | 13 Jul 2026 | | Positive Jemperli data in dMMR/MSI-H rectal cancer | RNS |
| 10/07/26 | 11:58:58 | 10 Jul 2026 | | Hansoh positive Phase III results for Riz-Rez | RNS |
| 09/07/26 | 15:30:00 | 9 Jul 2026 | | Director/PDMR Shareholding | RNS |
| 09/07/26 | 10:00:00 | 9 Jul 2026 | | Directorate change | RNS |
| 01/07/26 | 15:00:01 | 1 Jul 2026 | | Total Voting Rights | RNS |
| 29/06/26 | 15:00:00 | 29 Jun 2026 | | Holding(s) in Company | RNS |
| 29/06/26 | 15:00:00 | 29 Jun 2026 | | Transaction in Own Shares | RNS |
| 26/06/26 | 15:00:01 | 26 Jun 2026 | | Holding(s) in Company | RNS |
| 24/06/26 | 15:30:01 | 24 Jun 2026 | | Director/PDMR Shareholding | RNS |
| 24/06/26 | 14:52:05 | 24 Jun 2026 | | GSK announces tender offer to acquire Nuvalent | RNS |
| 23/06/26 | 15:30:01 | 23 Jun 2026 | | Director/PDMR Shareholding | RNS |
| 22/06/26 | 15:00:01 | 22 Jun 2026 | | Transaction in Own Shares | RNS |
| 17/06/26 | 16:06:03 | 17 Jun 2026 | | cUTI oral antibiotic Tebipenem approved by US FDA | RNS |
| 15/06/26 | 15:00:00 | 15 Jun 2026 | | Transaction in Own Shares | RNS |
| 12/06/26 | 07:00:06 | 12 Jun 2026 | | Momelotinib orphan drug designations for VEXAS | RNS |
| 11/06/26 | 15:30:01 | 11 Jun 2026 | | Director/PDMR Shareholding | RNS |
| 10/06/26 | 15:30:00 | 10 Jun 2026 | | Director/PDMR Shareholding | RNS |
| 09/06/26 | 17:51:15 | 9 Jun 2026 | | Dr Hal Barron – New Directorship | RNS |
| 09/06/26 | 07:00:01 | 9 Jun 2026 | | GSK enters agreement to acquire Nuvalent, Inc. | RNS |
